Search

Search Constraints

You searched for: Author/Creator Andersson, Per‐Ola

Search Results

1. Age is the most important predictor of survival in diffuse large B‐cell lymphoma patients achieving event‐free survival at 24 months: a Swedish population‐based study. (5th May 2021)

3. Cell‐of‐origin determined by both gene expression profiling and immunohistochemistry is the strongest predictor of survival in patients with diffuse large B‐cell lymphoma. Issue 1 (7th November 2019)

4. Expression of ribosomal and actin network proteins and immunochemotherapy resistance in diffuse large B cell lymphoma patients. (16th May 2018)

5. Long‐term survival and loss in expectancy of life in a population‐based cohort of 7114 patients with diffuse large B‐cell lymphoma. Issue 8 (20th June 2018)

6. Low response rate to ATG‐based immunosuppressive therapy in very severe aplastic anaemia — A Swedish nationwide cohort study. (10th April 2018)

8. Outcome and determinants of failure to complete primary R‐CHOP treatment for reasons other than non‐response among patients with diffuse large B‐cell lymphoma. Issue 7 (3rd April 2020)

9. Outcomes of relapsed/refractory diffuse large B‐cell lymphoma and influence of chimaeric antigen receptor T trial eligibility criteria in second line—A population‐based study of 736 patients. (25th April 2022)

10. Transcriptome sequencing of archived lymphoma specimens is feasible and clinically relevant using exome capture technology. Issue 1 (23rd October 2021)